Moderna Stock Soars 131% as Personalized mRNA Cancer Vaccine Hits Phase 3 Melanoma Goals
#breakthroughTherapyDesignation #interpath-001 #intismeranAutogene #mark-to-marketLosses #peterHillerberg #stageIib–ivMelanoma
#n#nile1
#breakthroughTherapyDesignation #interpath-001 #intismeranAutogene #mark-to-marketLosses #peterHillerberg #stageIib–ivMelanoma
#n#nile1
Moderna Stock Soars 131% as Personalized mRNA Cancer Vaccine Hits Phase 3 Melanoma Goals
Moderna shares surged 131% after its Phase 3 INTerpath-001 trial of intismeran autogene with Keytruda met primary melanoma endpoints, triggering $4.8B in short-seller losses.
nile1.com
August 19, 2026 at 5:01 PM
Moderna Stock Soars 131% as Personalized mRNA Cancer Vaccine Hits Phase 3 Melanoma Goals
#breakthroughTherapyDesignation #interpath-001 #intismeranAutogene #mark-to-marketLosses #peterHillerberg #stageIib–ivMelanoma
#n#nile1
#breakthroughTherapyDesignation #interpath-001 #intismeranAutogene #mark-to-marketLosses #peterHillerberg #stageIib–ivMelanoma
#n#nile1